SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is experiencing significant market volatility driven by reports of delays in its next-generation AI model, 'Avocado,' which has triggered debates over the company's aggressive infrastructure capital expenditures. While some market participants are expressing skepticism regarding Meta's ability to maintain a technological lead, bullish investors are actively using these price dips to accumulate shares, citing strong fundamental ad revenue and the long-term potential of the company's internal AI chip development.

Trump For President

The $TRUMP token is experiencing extreme volatility and intense social media debate, driven by a speculative promotional event involving potential gala invitations for top holders. Community discussion remains deeply polarized, with supporters highlighting the token's meme-driven momentum while critics aggressively label the project a manipulative grift and an "idiot tax" amidst ongoing geopolitical and political controversies.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as traders closely monitor high-stakes legal battles and federal intervention involving the restart of the Santa Ynez Unit and associated pipelines. The community is actively debating the potential for a massive short squeeze driven by the company's significant short interest, while weighing the impact of aggressive federal support against persistent regulatory and legal resistance from California.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating conversation among traders due to its low market capitalization and limited circulating supply, fueling speculation about potential for sharp price movements. Community members remain divided, with some actively accumulating in anticipation of an NFT market resurgence while others express frustration over stagnant performance and the need for broader exchange listings.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillos is attracting significant attention as investors speculate on a potential turnaround following a major leadership transition and ongoing expansion into new territories like Georgia. Community discussion is heavily focused on the stock's valuation relative to its strong brand loyalty and high-volume restaurant locations, with many investors actively debating whether the current price point represents an undervalued long-term opportunity or a symptom of broader restaurant sector headwinds.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang is trending due to significant momentum in the global low-altitude economy, fueled by the upcoming debut of the VT35 long-range eVTOL and confirmed commercial passenger flight operations set to begin in Saudi Arabia. Investors are actively debating the company's valuation gap compared to Western competitors, with many pointing to its unique regulatory certifications and operational milestones as key drivers for long-term growth despite recent market volatility.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

Fair Isaac Corp. (FICO) is seeing heavy volatility as investors weigh the stock's recent pullbacks against conflicting community sentiment regarding its competitive moat. While some traders are capitalizing on technical dips and betting on a rebound, others remain concerned about regulatory scrutiny and potential market share erosion from lower-cost alternatives.

Movement Network is a secure and scalable blockchain designed to make Move programming accessible to developers everywhere. With high-performance execution and security, Movement delivers the infrastructure for the next generation of decentralized applications and unleashes opportunity and financial empowerment for anyone, anywhere.  $MOVE is the native token of Movement Network, for transaction fees and staking to secure the network. The Movement M1 (Layer 1) Network is powered by the Move programming language, unleashing opportunity, accessibility, and financial empowerment for anyone, anywhere.

MarketMove

MarketMove (MOVE) is trending as traders analyze its role in the U.S. Treasury volatility market alongside its activity as a crypto token with a volatile, low-float structure. The community is actively debating its potential for momentum-driven price swings, with many discussing its speculative nature and comparing it to other recent market runners.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending as investors digest a confirmed 1-for-5 reverse stock split and a significant decline in recent dividend payouts, leading to intense debate over the fund's long-term sustainability. The community remains polarized, with some traders actively rotating positions to hedge volatility while others express frustration over severe NAV erosion.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors weigh strong comparable sales growth and digital expansion against lingering concerns regarding premium valuation and legal headwinds. The community is actively discussing the retailer's ability to maintain its defensive, membership-driven model while monitoring potential tariff-related litigation and volatility around the upcoming earnings release.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo.</li><li>The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.</li><li>The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator.</li></ul>Novo Nordisk AS’s (NVO) deal with Hims &amp; Hers Health Inc. (HIMS) has turned Wall Street bullish on both companies, with analysts stating that it helps them in dealing with a commercial headwind and removes a litigation risk from the equation.According to TheFly, analysts at BMO Capital noted that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">Novo Nordisk-Hims deal</a> to sell branded GLP-1 is a significant step forward in helping the Ozempic maker address a commercial headwind.The firm maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were down about 1% in Tuesday’s pre-market trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up nearly 5% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">Why Are Analysts Bullish On HIMS?</h2>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo. The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator. BofA sees the risk-to-reward ratio as balanced now following the deal.Deutsche Bank also hiked its price target for HIMS to $28 from $25, implying an upside of more than 26% from Monday’s closing price. The firm cited the Novo deal for its price target hike, while keeping a ‘Hold’ rating on the HIMS stock.<h2 class="st-heading-2">What Did Novo, Hims Agree On?</h2>Hims and Novo Nordisk announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company’s platform.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered. It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are covered.It added that these Ozempic and Wegovy offerings will be made available on its platform later this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user on Stocktwits believes selling HIMS stock at this point will be one of the “biggest mistakes” of their life.&nbsp;<stembedurl>https://stocktwits.com/TradeOrGoHome/message/647084706</stembedurl>Another user stated that every dip in the NVO stock is a “gift.”<stembedurl>https://stocktwits.com/King_of_the_bagholders/message/647086431</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 22% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 32%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-war-hegseth-most-intense-day-of-strikes-iranian-leaders-scrambling/cZdoAnzRI75">Iran War: Defense Secretary Hegseth Warns Of ‘Most Intense’ Strikes, Says The Middle East Country Is ‘Badly Losing’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Equity

<ul class="summary-bullets"><li>Hims &amp; Hers said that existing patients will have the opportunity to transition to FDA-approved medicines when their providers deem it clinically appropriate.</li><li>The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered.</li><li>It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.</li></ul>Shares of Hims &amp; Hers Health Inc. (HIMS) surged more than 52% in Monday’s pre-market trading after Novo Nordisk A/S (NVO) partnered with the telehealth platform to offer Ozempic as well as Wegovy at affordable self-pay prices and dropped its patent infringement lawsuit against the company.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. Existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers, the company said.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 2% in Monday’s opening trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up around 39% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">What Does The Agreement Include?</h2>Hims &amp; Hers stated that the Ozempic and Wegovy offerings will be made available on its platform later this month.This includes Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg and will also include Wegovy injections in doses of 1.7 mg and 2.4 mg. Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.Over the coming months, Hims &amp; Hers will educate U.S. weight loss customers about their options across a wider range of FDA-approved treatments. When providers determine it is clinically appropriate, the company will help support a smooth transition to these medications, the company said.<h2 class="st-heading-2">Novo’s Allegations</h2>In&nbsp;February this year, Novo had sued Hims &amp; Hers,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">stating</a> that the latter is duping consumers and healthcare professionals about the clinical benefits and safety of these unapproved drugs.The U.S. Food and Drug Administration (FDA) also warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.&nbsp; We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act,” the agency said.Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 33%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">ImmunityBio Resubmits Supplemental Biologics License Application To FDA For Ankitva — IBRX Stock Declines Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

<ul class="summary-bullets"><li>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.</li><li>The company said this will also benefit patients who pay out of pocket, but their costs are tied to the list price of these drugs.</li><li>Novo Nordisk said this applies to patients with high-deductible health plans or co-insurance benefit designs.</li></ul>Novo Nordisk AS (NVO) is planning to cut Ozempic and Wegovy prices in the U.S. by up to 50% starting in 2027.Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company. This is a 50% reduction when compared to the current list price of Wegovy, and about 35% cut for the list price of Ozempic.“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” said Jamey Millar, Novo Nordisk’s Executive Vice President of U.S. operations.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were down nearly 2% in Tuesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Who Will Benefit From These Lower Prices?</h2>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.This will also benefit patients who pay out of pocket, but whose costs are linked to the list price of these drugs. This applies to patients with high-deductible health plans or co-insurance benefit designs, the company said.Novo Nordisk added that Tuesday’s price cuts do not impact its direct-to-consumer and self-pay offerings of Ozempic and Wegovy.<h2 class="st-heading-2">Ozempic And Wegovy Prices For Cash-Paying Patients</h2>Novo Nordisk currently offers Wegovy for cash-paying patients, starting at $149 per month for the pill and $199 per month for the pen.Ozempic prices start at $199 a month for the first two months for new patients for 0.25 mg and 0.5 mg doses.Existing patients can get Ozempic in 0.25 mg, 0.5 mg, and 1 mg doses at $349 per month.All patients will have to pay $499 a month for the 2 mg dose of Ozempic.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 24% year-to-date and 56% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-stock-soars-on-meta-expanded-6-gigawatt-deal-for-amd-gpus/cZRvDZZR4Cb">AMD Stock Soars Pre-Market After Meta Expands Multi-Year AI Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Still life of Novo Nordisk's Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, and Wegovy

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

<ul class="summary-bullets"><li>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements when compared to placebo on key secondary endpoints.</li><li>Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, compared to 2% in the placebo group.</li><li>The company’s Chief Scientific Officer, Martin Holst Lange, added that Novo Nordisk is looking forward to reporting data from a global trial with UBT251 next year.</li></ul>Novo Nordisk AS (NVO) on Tuesday announced that its phase 2 clinical trial of a new obesity drug in China has shown successful results.Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.However,&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> declined nearly 3% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">UBT251 Trial Results Show Significant Improvements</h2>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements compared with placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids.The trial investigated the safety and efficacy of UBT251 at doses of 2 mg, 4 mg, and 6 mg.Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, or about 17.5 kg, compared to 2% or 1.6kg in the placebo group after 24 weeks of treatment.“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Novo Nordisk’s Chief Scientific Officer, Martin Holst Lange.Lange added that the company is looking forward to reporting data from a global trial with UBT251 next year.<h2 class="st-heading-2">Why Is NVO Stock Declining Pre-Market?</h2>Novo Nordisk shares continued to decline in Tuesday’s pre-market session. This is after a fall of more than 16% on Monday, following the company's announcement that CagriSema demonstrated 23% weight loss in people with obesity in the Redefine 4 trial,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvo-stock-falling-pre-market-today/cZRtZlKR4UC">failing to meet</a> its primary endpoint.According to TheFly, analysts at JPMorgan downgraded Novo Nordisk to ‘Neutral’ from ‘Overweight’, calling the CagriSema results “disappointing.”The firm also further reduced its CagriSema forecasts by up to 63% through 2030, expecting a more challenging uptake for the product given its "inferiority" to Eli Lilly and Co.’s (LLY) Zepbound.Analysts at Kepler Cheuvreux downgraded NVO to ‘Hold’ from ‘Buy’ and stated that the company’s Redefine 4 study was a “major negative surprise.”Nordea analysts also downgraded Novo Nordisk to ‘Hold’ from ‘Buy’, with the firm citing a lack of near-term catalysts following Monday’s obesity study results.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date and 55% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-microsoft-down-current-status/cZRtw5dR4yV">Is Microsoft Down? MSFT 365 Error Reports Spike On Downdetector, Company Says It Is Investigating The Issue</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

<ul class="summary-bullets"><li>The company stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.</li><li>People treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg, according to Novo.</li><li>When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.</li></ul>Novo Nordisk AS (NVO) shares fell more than 14% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> trended in the ‘extremely bearish’ territory at the time of writing.<h2 class="st-heading-2">CagriSema Fails To Match Tirzepatide In Effectiveness</h2>Novo Nordisk stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.The company said that people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg.When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.“CagriSema has the potential to be the first GLP-1/amylin-combination product to reach the market for people living with obesity, documenting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to what has been observed with GLP-1 biology alone,” said Novo Nordisk’s Chief Scientific Officer and Executive Vice President, Martin Holst Lange.<h2 class="st-heading-2">Who Is CagriSema Aimed At?</h2>CagriSema is a once-weekly subcutaneous treatment that is being investigated by Novo Nordisk for adults with overweight or obesity issues. It is also being considered as a treatment for adults with type 2 diabetes.The treatment is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg.Novo Nordisk says CagriSema works by inducing weight loss by reducing hunger, increasing feelings of fullness, which helps people eat less and reduce their calorie intake.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date and 46% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-replicate-most-tariffs-after-supreme-court-ruling-goldman-sachs/cZRNfSqR4xV">Trump Administration Can Replicate Most Of The Tariffs, Says Goldman Sachs Following Supreme Court Rebuke: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is NVO Stock Falling Pre-Market Today?

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

<ul class="summary-bullets"><li>It is unclear what the company intends to charge for the vials, the report said.</li><li>Unlike Novo, Eli Lilly and Company already sells its obesity drug Zepbound in both injector pen and vial formats. &nbsp;</li><li>Novo also has a pill version of its obesity drug called Wegovy pill launched in early January to regain its slipping market share in the obesity segment.</li></ul>Danish drugmaker Novo Nordisk (NVO) is reportedly looking to sell its injectable Wegovy in vials in a move that mirrors rival Eli Lilly and Company (LLY).Bloomberg<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-11/novo-to-follow-lilly-and-sell-obesity-shot-wegovy-in-vials?srnd=homepage-americas"> reported </a>on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year, followed by launches in other countries.It is unclear what the company intends to charge for the vials, the report said. &nbsp;<h2 class="st-heading-2">Wegovy Upgrade</h2>Presently, Novo sells Wegovy in injector pens. Unlike Novo, Eli Lilly sells its obesity drug Zepbound in both injector pen and vial formats. The vials were introduced about two years ago to increase supply, improve access, and offer a lower-cost option.Injector pens are the standard auto-injector devices, often preferred for ease of use as they do not require manual drawing of medication. Meanwhile, vials require the use of a separate needle and syringe to draw up the medication.Novo also has a pill version of its obesity drug called Wegovy pill launched in early January as it pushes to regain its slipping market share in the obesity segment.<h2 class="st-heading-2">Novo’s Disappointing Outlook</h2>Novo now <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-shares-tumble-on-q4-miss-weak-sales-forecast/cZbi6tLR4m0">expects</a> adjusted sales to fall between 5% and 13% in fiscal 2026, and operating profit could decline by up to 13%.The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S. while issuing the guidance earlier this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stock stayed within ‘bearish’ territory over the past 24 hours, while message volume fell from ‘extremely high’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/entx-rallies-as-insiders-buy-company-shares/cZb6pAeR4Ah">ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly 

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

<ul class="summary-bullets"><li>The FDA stated that the totality of the claims made by Novo in the ad misleadingly suggests that, because of its pill form, Wegovy offers an advancement or improvement over other currently approved GLP-1 treatments for weight loss.</li><li>The agency pointed to terms such as “live lighter” and “a way forward” to argue that the Novo advertisement misleadingly implies greater weight loss than other currently approved GLP-1 treatments.</li><li>The FDA has sought a reply from Novo within 15 working days from the date of receipt.</li></ul>A television advertisement by Novo Nordisk A/S (NVO) for its obesity pill Wegovy has been flagged as “misleading” by the U.S. Food and Drug Administration (FDA).According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy. It added that this violates the distribution provisions of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 8% in Monday’s opening trade, but pared some of the gains to hover nearly 4% higher at the time of writing. Retail sentiment around the NVO stock trended in the ‘bullish’ territory on the platform.“We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” said Liz Skrbkova, Novo’s head of U.S. media and stakeholder relations, according to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/09/fda-novo-nordisk-wegovy-tv-ad.html">report</a>.<h2 class="st-heading-2">What Is The FDA Objecting To?</h2>The FDA stated that the totality of the claims made by Novo in the TV advertisement misleadingly suggests that, because of its pill form, Wegovy offers an advancement or improvement over other currently approved GLP-1 treatments for weight loss.“Specifically, these claims and presentations misleadingly imply that Wegovy in pill form uniquely enables patients to achieve outcomes that were not previously possible with other GLP-1 treatments for weight loss,” the FDA stated in its letter.In particular, the agency pointed to terms such as “live lighter” and “a way forward” to argue that the Novo advertisement misleadingly implies greater weight loss than other currently approved GLP-1 treatments, even though this has not yet been demonstrated.Beyond this, the FDA stated that the advertisement implies additional benefits such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives, positioning the pill as a solution to broader life problems rather than just a specific physical condition.The agency has sought a reply from Novo within 15 working days of receipt.<h2 class="st-heading-2">Novo’s Legal Battle With Hims &amp; Hers</h2>The FDA letter comes amid Novo’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">legal battle</a> with Hims &amp; Hers Health Inc. (HIMS). The Wegovy-maker sued Hims &amp; Hers, calling for a permanent ban on the company’s sales of unapproved, compounded drugs that infringe its patents.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process,” the company said.Last week, the FDA warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 4% year-to-date and 43% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

<ul class="summary-bullets"><li>Novo also stated that Hims &amp; Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.</li><li>Last week, the U.S. Food and Drug Administration warned of a crackdown last week on GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs.</li><li>Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.</li></ul>Novo Nordisk A/S (NVO) on Monday stated that it has filed a lawsuit against Hims &amp; Hers Health Inc. (HIMS), calling for a permanent ban on the company’s sales of unapproved, compounded drugs that infringe its patents.Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 5% in Monday’s pre-market trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were down more than 19% at the time of writing. Retail sentiment around the NVO stock trended in the ‘bullish’ territory on the platform.<h2 class="st-heading-2">Novo Accuses HIMS Of Duping Consumers</h2>Novo stated that Hims &amp; Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process – that’s dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective,” said Novo Nordisk’s senior vice president, Group General Counsel, Global Legal, IP and Security, John F. Kuckelman.The company also announced a share repurchase program on Monday of up to DKK 15 billion ($2.4 billion to be executed during a 12-month period beginning Feb. 4, 2026.<h2 class="st-heading-2">FDA Warns Of Crackdown On Compounded GLP-1 Drugs&nbsp;</h2>Last week, the U.S. Food and Drug Administration (FDA) warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.&nbsp; We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act,” the agency said.Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.<h2 class="st-heading-2">Analysts Warn Of Sales Hit</h2>The FDA crackdown has resulted in sharp price target cuts from analysts, according to TheFly.Analysts at Citi warned that Hims &amp; Hers’ launch of the compounded pill version of Wegovy is “risky and aggressive,” and that it brings more legal risk to the company.The firm trimmed its price target for Hims &amp; Hers to $16.5 from $30, while maintaining a ‘Sell’ rating. Citi analysts stated that the new price target factors in a 25% bear case probability of Hims &amp; Hers losing all weight loss drug sales, a 60% base case probability of the company losing half of the sales, and a 15% bull case probability of limited GLP-1 downside from the legal challenges.Analysts at BofA also lowered their price target for the HIMS stock to $21 from $26, while keeping an ‘Underperform’ rating. The firm noted that the FDA did not make a distinction between oral and injectable products in its crackdown warning.This leads BofA analysts to believe that the FDA’s crackdown could extend beyond APIs for oral GLP-1 treatment and include APIs for injectable semaglutide as well. The firm believes this adds a new risk to Hims' injectable GLP-1 franchise.<h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers</a> trended in the ‘extremely bullish’ territory at the time of writing.One user pointed out that the company’s legal battle with Novo hasn’t even started yet.<stembedurl>https://stocktwits.com/weqwewqeq1111/message/644437840</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 29%.$1 = DKK 6.30Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pgy-stock-rising-today-ahead-of-ai-lenders-q4-earnings/cZbHxXpR48v">PGY Stock Pops Pre-Earnings: Wall Street Bets On Pagaya’s AI-Powered Lending Model</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

French pharmaceutical major Sanofi SA (SNY) on Tuesday reportedly launched a vaccine manufacturing facility in Vietnam with Vietnam Vaccine JSC (VNVC). Following the news, Nasdaq-listed shares of Sanofi traded 2% higher in Tuesday’s premarket.The new facility is designed to produce vaccines for use in Vietnam as well as for export, according to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-vnvc-launch-vaccine-factory-vietnam-2025-05-27/">report</a>. It added that French President Emmanuel Macron, who is currently visiting Vietnam, witnessed the launch.The plant spans 2.6 hectares and is situated in Long An. It has received an initial investment of two trillion dong ($77.15 million), the report said, citing a statement from VNVC.The new facility is slated to produce 100 million vaccine doses annually, although it is unclear which vaccines will be produced.Operations are expected to begin by 2027-end, the report added.Sanofi, renowned for its vaccines, reported an 11.4% surge in vaccine sales in the first quarter to €1.3 billion ($1.48 billion). The company’s total sales in the quarter came in at €9.9 billion, marking an increase of 9.7% at constant exchange rate.Sanofi makes vaccines against RSV lung infection, Polio, Influenza, whooping cough, and Meningitis, among others. The company is also developing and studying a vaccine against Chlamydia.The company stated that over 500 million people are vaccinated annually with its vaccines worldwide, and it supplies 2.5 million vaccine doses every day.On Stocktwits, retail sentiment around SNY stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_7_21_45_AM_png_e41808b018.webp" alt="SNY's Sentiment Meter and Message Volume as of 7:20 a.m. ET on May 27, 2025 | Source: Stocktwits" width="628" height="63"><figcaption>SNY's Sentiment Meter and Message Volume as of 7:20 a.m. ET on May 27, 2025 | Source: Stocktwits</figcaption></figure> According to Koyfin data, 16 of 21 analysts covering Sanofi rate it ‘Buy’ or higher, while five rate it a ‘Hold’.<a href="https://stocktwits.com/symbol/SNY">SNY stock</a> is up by about 8% this year and by over 8% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/info-edge-tests-key-support-sebi-ra-financial-sarthis-says-breakout-above-1-510-could-signal-upside/ch0VIWGRbAz">Info Edge Tests Key Support: SEBI RA Financial Sarthis Says Breakout Above ₹1,510 Could Signal Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: 1 Vietnamese Dong = 0.000039 USD &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1 Euro = 1.14 USD

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive

According to Reuters, operations at the new facility are expected to begin by the end of 2027. 

PVAL
Putnam ETF Trust - Putnam Focused Large Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PVAL News

PVALPutnam ETF Trust - Putnam Focused Large Cap Value ETF